Knowledge about the surface antigens of malignant melanoma has grown rapidly since the advent of monoclonal antibodies (1) (2) (3) (4) (5) . A large number of cell lines derived from melanomas have now been established, and these have facilitated the serological analysis of melanoma surface antigens. Many of the melanoma antigens that have been identified with mouse monoclonal antibodies are not expressed by all melanoma lines but show instead a differential pattern of expression that defines melanoma subsets on the basis of surface antigenic phenotype. It seems likely that this diversity of melanoma phenotype reflects a corresponding diversity in the surface phenotype of normal cells undergoing melanocyte differentiation. To pursue this idea, we analyzed the surface antigens of melanocytes, using a recently described method for growing melanocytes from normal skin (6). Most, but not all, of the antigens initially detected on melanomas were also detected on melanocytes, and the pattern of antigen expression on newborn and adult melanocytes could be distinguished. From these studies of melanocytes and melanomas, we propose a scheme of surface antigenic changes occurring during melanocyte differentiation and a classification of melanoma based on expression of melanocyte differentiation antigens.
assays were performed as described previously (3, 8) . Indicator cells were prepared by conjugating purified anti-mouse immunoglobulin (Dako Corp., Santa Barbara, CA) or protein A (Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, N J) to human erythrocytes using 0.01% chromium chloride. Assays were performed in Falcon 3040 Microtest II plates (Falcon Labware, Div. of Becton, Dickinson & Co., Oxnard, CA). Sera were incubated with target cells for 1 h at 20°C. Target cells were then washed, and indicator cells were added for 1 h. Plates were washed and evaluated for rosetting by light microscopy. Titers corresponded to the serum dilution giving 50% positive target cells. Absorption tests were carried out as described (3, 7, 8) . Table I ). Monoclonal antibodies were derived from spleen cells of mice immunized with melanoma, glioma, renal cancer, or melanocyte cell cultures (3, 9, I0; A.
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TABLE I

Panel of Mouse Monoclonal Antibodies Detecting Cell Surface Antigens of Melanomas and Melanocytes
These sera had maximum titers of ~-~10 -4, and usually >10 -5, with melanoma or melanocyte cultures. With the exception of M-18 antibody, which was detected by PA assays, all other mouse monoclonal antibodies were analyzed using the anti-Ig assay. Monoclonal antibodies known to identify the same epitope or different epitopes on the same molecule were grouped under the same antigenic system; M-19 antigen is a 95-kd glycoprotein detected by four mouse monoclonal antibodies, M-20 represents a 130-kd glycoprotein detected by five different mouse monoclonal antibodies, and M-23 is a glycoprotein dimer of 145 kd and 100 kd detected by two antibodies. Mouse monoclonal antibody and conventional rabbit antisera to/32-microglobulin (018b) were purchased from Accurate Chemical and Scientific Corp., Westbury, NY. Serological and biochemical characteristics of the human HLA-DR monoclonal antibody 13-17 have been published (1, 11) . Antigen M-9 was detected by a naturally occurring antibody in the serum of a healthy individual; this antibody defines a melanocyte differentiation antigen, Mel-1, which is expressed by ~50% of melanoma cell lines (12) .
Tyrosinase Assay. Tyrosinase activity was measured using a modification of the assay described by Pomerantz (13) .
[3H]Tyrosine (specific activity, 53.1 Ci/mMol) was purchased from New England Nuclear (Boston, MA). Cell lines to be tested were seeded at a density of 1 X 10 6 cells per flask in 25 cm 2 Falcon flasks. After 12 h, medium was removed and replaced with 4 ml fresh medium containing 5 pCi [3H]tyrosine, and the cultures were incubated for an additional 24 h. Residual [3H]tyrosine in the medium was removed by adsorption to activated charcoal and passage over a Dowex 50w column (Bio-Rad Laboratories, Richmond, CA). Tritiated H20 (generated by tyrosinase activity) in the eluent was counted in triplicate in a LS 9000 Beckman Scintillation Counter (Beckman Instruments, Inc., Fullerton, CA). Tyrosinase activity was expressed as the ratio of tritiated H20 generated by melanoma cell lines per tritiated H20 generated by a control nonpigmented renal cancer cell line (SK-RC-7).
Results
Description of Antibodies Reactive with Cell Surface Antigens of Melanoma and Melanocytes.
The panel of typing antibodies used in this study is described in Table I , and reactivity and titer of these antibodies with melanoma cell lines are shown in Table II . and only weakly or not at all on most newborn melanocytes: M-9 and M-10; and (d) detected equally on both newborn and adult melanocytes: M-11 to M-34. Most of the antigens in this last group were also expressed by the majority of melanoma cell lines. M-34 antigen was an exception in this regard, as it was detected on only 2/30 melanoma cell lines, as compared with 14/14 fetal, newborn, and adult melanocyte cultures. The monoclonal antibody recognizing M-34 detects a 120,000 Mr glycoprotein that is expressed by renal cancer, normal kidney epithelium, and a limited number of nonrenal cells (9) . 24 other monoclonal antibodies detecting a series of differentiation antigens on renal cancer, lung cancer, and ovarian cancer and ABH blood group antigens were included in these tests. No reactions with newborn or adult melanocytes were observed.
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Influence of In Vitro Culture Conditions on Antigen Expression.
Melanocytes require TPA and cholera toxin for at least the first 4 d of culture to stimulate melanocyte proliferation and to inhibit overgrowth of keratinocytes and fibroblasts. However, after this brief exposure, cultures can be maintained without growth factors for several weeks before melanocytes die or become overgrown by fibroblasts. To investigate the influence of growth factors on antigen expression, melanocytes were grown for 4 d in TPA and cholera toxin conditioned media and then for 3 wk in (a) culture medium without growth factors, (b) culture medium with either TPA or cholera toxin, or (c) culture medium with both TPA and cholera toxin. We did not observe any difference in antigen expression when melanocytes were cultured under these various conditions; monoclonal antibodies detecting antigens M-1 through M-6, M-9, M-10, and M-34 were used in these tests. Studies were also carried out to determine whether melanoma cell lines grown in the presence of TPA and cholera toxin would change their surface antigenic phenotype. Of the 28 antigenic systems tested on 8 melanoma cell lines, only M-34 antigen was influenced by the presence of growth factors; SK-MEL-19, which characteristically expresses little or no M-34 antigen, converted to M-34 + after growth in TPA and cholera toxin.
To reduce the possibility that length of time in culture might alter antigen expression, most tests were carried out with melanocyte cultures between passage 1 and 3. However, little difference in antigen expression was seen when melanocytes were tested later at passage 8, 12, or 19. M-4 and M-5 antigens, which are markers of newborn and fetal melanocytes, appear to be exceptions because they could not be \ detected on newborn melanocytes after five passages in culture.
Subsets of Melanoma Cell Lines Defined by Melanocyte Differentiation
Antigens. 25 melanoma cell lines were typed for the expression of M-2, M-3, HLA-DR, M-4, M-6, M-9 and M-10 antigens. These seven antigens were selected because they defined subsets of melanomas (present on some melanomas but not others) and had distinct patterns of expression on fetal/newborn and adult melanocytes. Three antigens, HLA-DR, M-2, and M-3, can be assumed to be early markers of melanocyte differentiation because they are expressed on melanomas but not on melanocytes. Antigens M-4 and M-6 appear on fetal and newborn melanocytes but not adult melanocytes and, therefore, signal an intermediate phase in melanocyte differentiation. M-9 and M-10 appear to be late markers in the melanocyte lineage because they are strongly (Fig. 4) . Evidence for the significance of these differences comes from a comparison of the pattern of surface antigens with other differentiation characteristics, such as pigmentation, morphology, and tyrosinase (Fig. 4) . The majority of melanomas expressing early antigenic markers are epithelioid (Fig. 5a ), and these melanoma lines lack pigmentation and tyrosinase activity. Fig. 5b shows the morphology of a cell line belonging to the intermediate group, and the resemblance to the bipolar morphology of melanocytes from fetal and newborn skin is apparent. Melanomas expressing late melanocyte markers frequently have a polydendritic morphology similar to adult melanocytes, with heavy pigmentation and high levels of tyrosinase activity (Fig. 5 c) .
Melanocyte Differentiation Pathway. From these studies of differentiation antigens on melanocytes and melanomas, a surface antigenic map of the melanocyte lineage can be proposed (Fig. 6) . At least three distinct stages in melanocyte differentiation can be defined -precursor, intermediate, and mature. We infer the features of melanocyte precursors from the characteristics of melanomas expressing early markers of differentiation. The intermediate and mature phases of melanocyte development are defined by markers that distinguish fetal/newborn melanocytes from adult melanocytes. On the basis of surface antigens, morphology, pigmentation, and tyrosinase activity, three classes of melanomas can be identified, corresponding to the features of normal melanocytes at the early, intermediate, or mature phases in melanocyte differentiation.
Discussion
The process of cellular differentiation is accompanied by changes in the surface antigenic phenotype, and surface antigens that distinguish cells belonging to distinct differentiation lineages or distinguish cells at different phases in the same differentiation lineage are referred to as differentiation antigens (14) . Initial recognition of differentiation antigens came about through analysis of surface antigens of T cell leukemias of the mouse and the description of the TL (15), Thy-1 (16) , and Lyt (17) series of antigens. The analysis of these T cell differentiation antigens was greatly simplified by the availability of normal T cells from the thymus and from other lymphoid organs for a side-by-side comparison with leukemic T cells. Although the study of differentiation antigens on T cells and B cells of mouse and man is relatively advanced, little is known about differentiation antigens displayed on normal and neoplastic cells belonging to other lineages, and this is due to the difficulty of obtaining a ready source of the appropriate normal cell type. The recently described technique to culture melanocytes from normal skin (6) provides a renewable source of proliferating cells for the analysis of melanocyte differentiation antigens, and the monoclonal antibodies detecting cell surface antigens of melanoma provide the initial serological probes for this analysis.
On the basis of reactions with melanocytes from fetal, newborn, or adult skin, we identified antigens that appear to be early, intermediate, or late markers ofmelanocyte differentiation. The late markers, such as M-10, are strongly expressed by adult melanocytes. Intermediate melanocyte markers, such as M-4, are found on fetal and newborn melanocytes but not adult melanocytes. With regard to antigens detected on melanomas but not on fetal, newborn, or adult melanocytes, we propose that these are early markers expressed by melanocyte precursors but not by ceils further down the melanocyte pathway. Although a melanocyte precursor cell has not as yet been identified in the skin, we suggest that its surface phenotype would correspond to the M-2 +, M-3 +, HLA-DR + subset of melanomas. One candidate for the melanocyte precursor is the indeterminate cell type found in the basal layer of the epidermis (18) . Because these cells express HLA-DR but do not contain melanosomes or tyrosinase activity, they have been considered precursors of Langerhans cells in the upper epidermis, but it is equally plausible that some indeterminate cells are precursors of melanocytes. Two other explanations for the expression of antigens on melanoma cells but not melanocytes should be considered. One possibility is that a second differentiation pathway for pigment cells exists. A bifurcation could occur in the neural crest pathway, with one arm leading to epidermal melanocytes and another arm leading to nevus cells. HLA-DR, M-2, and M-3 would be expressed only on nevus cells and pigmented tumors derived from them, hut not on normal or malignant melanocytes. The other possibility, which we consider less likely, is that these antigens are unrelated to neural crest differentiation but are the result of abnormal gene expression induced during the process of malignant transformation and tumor progression.
In addition to the value that these melanocyte differentiation markers have for investigating normal melanocytes and their precursors, it seems likely that such markers will also provide new ways to analyze and classify melanomas. For instance, melanoma cell lines fall into one of three general classes on the basis of expression of early, intermediate, or late melanocyte antigens. Although the significance of this classification awaits the results of comparable studies with noneuhured tissue specimens, there is an evident correlation between the surface antigenic phenotype of the cultured melanoma line and other differentiation characteristics, such as morphology, pigmentation, and tyrosinase activity. Melanomas expressing early markers but lacking intermediate or late markers have an epithelioid morphology, lack pigmentation, and have low levels of tyrosinase. In contrast, melanomas expressing late markers, such as M-9 and M-10, have a spindle-shaped or polydendritic morphology, are pigmented, and have high levels of tyrosinase. Intermediate classes of melanoma can be distinguished that express intermediate melanocyte markers, and these generally have a spindle morphology, little pigmentation, and low levels of tyrosinase.
A question that cannot be answered with the available evidence is whether melanomas arise at any one of a number of stages throughout the melanocyte lineage or whether there is a preferential stage for malignant transformation. The finding that the phenotypes of melanoma correspond to distinct phases in the melanocyte pathway could be explained by transformation of early, intermediate, or mature progenitors, or alternatively, by transformation of early progenitors with transformants having the ability to undergo variable but characteristic degrees of differentiation to later stages of melanocyte differentiation. The overlapping phenotypic characteristics of melanoma cell lines from different individuals is consistent with either explanation. However, the striking phenotypic variation of different melanoma metastases derived from a single patient (19) , where individual metastases were found to show characteristics of either early or intermediate melanocyte stages, is more consistent with a model of early stage transformation and variable capacity of progeny cells to differentiate toward later stages. This matter may be clarified by the results of current attempts to transform melanocytes from different stages of differentiation with chemical or physical carcinogens.
Summary
The surface antigens of melanocytes from newborn and adult skin have been analyzed with monoclonal antibodies detecting cell surface antigens of malignant melanoma. Antigenic markers that distinguish early, intermediate, and mature stages in melanocyte differentiation have been defined. The characteristics of the normal melanocyte precursor have been inferred from the features of melanomas that express early markers of melanocyte differentiation. A rudimentary surface antigen map of cells undergoing melanocyte differentiation and a new classification of melanomas based on the expression of melanocyte differentiation antigens are proposed.
